Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements...
Saved in:
| Published in | Journal of gynecologic oncology Vol. 35; no. 2; pp. e45 - 13 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
01.03.2024
대한부인종양학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2005-0380 2005-0399 2005-0399 |
| DOI | 10.3802/jgo.2024.35.e45 |
Cover
| Abstract | The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements: Population, Intervention, Comparison, and Outcome framework. These elements include the evaluation of the efficacy and safety of immune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patients who have failed platinum-based chemotherapy, as well as the effect of combined treatment with trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally, the guideline assessed the efficacy and safety of omitting lymph node dissection in low-risk endometrial cancer patients, investigated the effect of sentinel lymph node mapping in early-stage endometrial cancer surgery, addressed the outcome of chemoradiation therapy as a postoperative treatment in patients with advanced (stage III-IVA) endometrial cancer, and explored the impact of initial treatment with immune checkpoint inhibitors on survival in patients with advanced or recurrent endometrial cancer patients. |
|---|---|
| AbstractList | The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements: Population, Intervention, Comparison, and Outcome framework. These elements include the evaluation of the efficacy and safety of immune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patients who have failed platinum-based chemotherapy, as well as the effect of combined treatment with trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally, the guideline assessed the efficacy and safety of omitting lymph node dissection in low-risk endometrial cancer patients, investigated the effect of sentinel lymph node mapping in early-stage endometrial cancer surgery, addressed the outcome of chemoradiation therapy as a postoperative treatment in patients with advanced (stage III-IVA) endometrial cancer, and explored the impact of initial treatment with immune checkpoint inhibitors on survival in patients with advanced or recurrent endometrial cancer patients.The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements: Population, Intervention, Comparison, and Outcome framework. These elements include the evaluation of the efficacy and safety of immune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patients who have failed platinum-based chemotherapy, as well as the effect of combined treatment with trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally, the guideline assessed the efficacy and safety of omitting lymph node dissection in low-risk endometrial cancer patients, investigated the effect of sentinel lymph node mapping in early-stage endometrial cancer surgery, addressed the outcome of chemoradiation therapy as a postoperative treatment in patients with advanced (stage III-IVA) endometrial cancer, and explored the impact of initial treatment with immune checkpoint inhibitors on survival in patients with advanced or recurrent endometrial cancer patients. The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements: Population, Intervention, Comparison, and Outcome framework. These elements include the evaluation of the efficacy and safety of immune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patients who have failed platinum-based chemotherapy, as well as the effect of combined treatment with trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally, the guideline assessed the efficacy and safety of omitting lymph node dissection in low-risk endometrial cancer patients, investigated the effect of sentinel lymph node mapping in early-stage endometrial cancer surgery, addressed the outcome of chemoradiation therapy as a postoperative treatment in patients with advanced (stage III–IVA) endometrial cancer, and explored the impact of initial treatment with immune checkpoint inhibitors on survival in patients with advanced or recurrent endometrial cancer patients. The committee of uterine corpus cancer of the Korean Society of Gynecologic Oncology developed updated guideline for treatments of uterine corpus cancer patients. Evidences of recommendation according to each key question were evaluated using systematic review and meta-analysis. The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements: Population, Intervention, Comparison, and Outcome framework. These elements include the evaluation of the efficacy and safety of immune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patients who have failed platinum-based chemotherapy, as well as the effect of combined treatment with trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally, the guideline assessed the efficacy and safety of omitting lymph node dissection in low-risk endometrial cancer patients, investigated the effect of sentinel lymph node mapping in early-stage endometrial cancer surgery, addressed the outcome of chemoradiation therapy as a postoperative treatment in patients with advanced (stage III-IVA) endometrial cancer, and explored the impact of initial treatment with immune checkpoint inhibitors on survival in patients with advanced or recurrent endometrial cancer patients. The Korean Society of Gynecologic Oncology (KSGO) had been making an effort tostandardize and enhance the quality of domestic uterine corpus cancer treatment bydeveloping updated clinical practice guidelines in 2021. The KSGO revised the guidelinesbased on a literature search using 4 key elements: Population, Inter vention, Comparison,and Outcome framework. These elements include the evaluation of the efficacy and safety ofimmune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patientswho have failed platinum-based chemotherapy, as well as the effect of combined treatmentwith trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally,the guideline assessed the efficacy and safety of omitting lymph node dissection in low-riskendometrial cancer patients, investigated the effect of sentinel lymph node mapping inearly-stage endometrial cancer surger y, addressed the outcome of chemoradiation therapy asa postoperative treatment in patients with advanced (stage III–IVA) endometrial cancer, andexplored the impact of initial treatment with immune checkpoint inhibitors on sur vival inpatients with advanced or recurrent endometrial cancer patients. KCI Citation Count: 0 |
| Author | Noh, Joseph J Suh, Dong Hoon Kim, Dae-Yeon Kim, Junhwan Choi, Min Chul Baek, Min-Hyun Kim, Yong Beom Hwang, Woo Yeon Joo, Won Duk Lee, Yong Jae Kim, Ju-Hyun |
| AuthorAffiliation | 4 Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea 2 Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 3 Department of Obstetrics and Gynecology, School of Medicine, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Korea 5 Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, College of Medicine, CHA University, Seongnam, Korea 7 Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea 6 Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea 1 Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea |
| AuthorAffiliation_xml | – name: 3 Department of Obstetrics and Gynecology, School of Medicine, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Korea – name: 4 Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea – name: 2 Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea – name: 6 Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea – name: 1 Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea – name: 7 Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea – name: 5 Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, College of Medicine, CHA University, Seongnam, Korea |
| Author_xml | – sequence: 1 givenname: Ju-Hyun orcidid: 0000-0003-4007-5739 surname: Kim fullname: Kim, Ju-Hyun organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea – sequence: 2 givenname: Dae-Yeon orcidid: 0000-0003-0180-9314 surname: Kim fullname: Kim, Dae-Yeon organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea – sequence: 3 givenname: Junhwan orcidid: 0000-0001-6807-1233 surname: Kim fullname: Kim, Junhwan organization: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea – sequence: 4 givenname: Joseph J orcidid: 0000-0002-3132-8709 surname: Noh fullname: Noh, Joseph J organization: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea – sequence: 5 givenname: Woo Yeon orcidid: 0000-0003-0231-8330 surname: Hwang fullname: Hwang, Woo Yeon organization: Department of Obstetrics and Gynecology, School of Medicine, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Korea – sequence: 6 givenname: Min-Hyun orcidid: 0000-0003-0423-9038 surname: Baek fullname: Baek, Min-Hyun organization: Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea – sequence: 7 givenname: Min Chul orcidid: 0000-0003-4509-6731 surname: Choi fullname: Choi, Min Chul organization: Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, College of Medicine, CHA University, Seongnam, Korea – sequence: 8 givenname: Won Duk orcidid: 0000-0003-4637-6946 surname: Joo fullname: Joo, Won Duk organization: Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, College of Medicine, CHA University, Seongnam, Korea – sequence: 9 givenname: Yong Jae orcidid: 0000-0003-0297-3116 surname: Lee fullname: Lee, Yong Jae organization: Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea – sequence: 10 givenname: Dong Hoon orcidid: 0000-0002-4312-966X surname: Suh fullname: Suh, Dong Hoon organization: Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea – sequence: 11 givenname: Yong Beom orcidid: 0000-0003-1196-369X surname: Kim fullname: Kim, Yong Beom organization: Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38216137$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003060799$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1kt1rFDEUxYNU7Ic--yZ5FGG3d_IxM_FFStFaLFS0PodM5mZMO5usyYywr_7lZnfbooIQuBfuOb8TkntMDkIMSMjLCpa8BXZ6O8QlAyaWXC5RyCfkiAHIBXClDh77Fg7Jcc63AHUDLXtGDnnLqrrizRH59TkZO3mLdJh9j6MPmKmLia5MMAOuMEw0OjpPmMqI2pjWc6bWBIuJ-kA_xYTmLTX7JtCv0XqcNlvPxSagjWMcvKXXYddtCiBkDLkw8mSmHf85eerMmPHFfT0h3z68vzn_uLi6vrg8P7taWMHUtGDYdFJ0IGomlXFStq6WtepF39lOIkKDnbDW8QoaZbjtOO9dXUMHjegqcPyEvNlzQ3L6znodjd_VIeq7pM--3FzqCkQ5UBfxu714PXcr7G25ZzKjXie_Mmmzs_49Cf57Af0sBCVa1apCeH1PSPHHjHnSK58tjqMJGOesmWIKOG8FK9JXf4Y9pjx8UxHIvcCmmHNCp60vz-fjNtuPJVRv10GXddDbddBc6rIOxXf6j-8B_T_Hb8vTuus |
| CitedBy_id | crossref_primary_10_1016_j_compbiomed_2025_109764 crossref_primary_10_1016_j_ijgc_2024_100068 crossref_primary_10_3802_jgo_2025_36_e71 |
| Cites_doi | 10.1016/j.ejso.2018.06.034 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P 10.1245/s10434-017-5816-4 10.1016/j.annonc.2023.10.034 10.1136/bmj.328.7454.1490 10.1136/jitc-2021-003777 10.1056/NEJMoa2302312 10.1016/j.ygyno.2019.03.254 10.1016/S0140-6736(08)61766-3 10.1016/j.ygyno.2017.01.013 10.1056/NEJMoa1813181 10.1093/jnci/djn397 10.1158/1078-0432.CCR-20-0953 10.1056/NEJMoa2108330 10.1016/j.ygyno.2018.08.022 10.3802/jgo.2019.30.e38 10.1056/NEJMoa2216334 |
| ContentType | Journal Article |
| Copyright | 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology 2024 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology |
| Copyright_xml | – notice: 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. – notice: 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology 2024 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
| DOI | 10.3802/jgo.2024.35.e45 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2005-0399 |
| EndPage | 13 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10410406 PMC10948989 38216137 10_3802_jgo_2024_35_e45 |
| Genre | Journal Article Review |
| GeographicLocations | Republic of Korea |
| GeographicLocations_xml | – name: Republic of Korea |
| GrantInformation_xml | – fundername: National Cancer Center grantid: NCC-2112570-3 – fundername: ; grantid: NCC-2112570-3 |
| GroupedDBID | 29K 2WC 5-W 53G 5GY 8JR 8XY 9ZL AAKDD AAYXX ABDBF ACUHS ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION D-I DIK DU5 E3Z EBD EF. F5P GROUPED_DOAJ HYE HZB OK1 RPM CGR CUY CVF ECM EIF NPM 7X8 5PM ABMYL ACYCR M~E |
| ID | FETCH-LOGICAL-c429t-2e7b54b046259af558f6569d4dbcb5ee07eb4ccf31079a3cb33df660b074b10f3 |
| ISSN | 2005-0380 2005-0399 |
| IngestDate | Sun Mar 17 03:18:43 EDT 2024 Thu Aug 21 18:34:46 EDT 2025 Thu Jul 10 22:42:06 EDT 2025 Wed Jul 30 01:47:41 EDT 2025 Tue Jul 01 02:37:35 EDT 2025 Thu Apr 24 23:07:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Sentinel Lymph Node Immune Checkpoint Inhibitor Survival Surgery Endometrial Neoplasm Trastuzumab |
| Language | English |
| License | 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c429t-2e7b54b046259af558f6569d4dbcb5ee07eb4ccf31079a3cb33df660b074b10f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 https://doi.org/10.3802/jgo.2024.35.e45 |
| ORCID | 0000-0003-4007-5739 0000-0001-6807-1233 0000-0003-4637-6946 0000-0003-0297-3116 0000-0003-4509-6731 0000-0003-0180-9314 0000-0002-3132-8709 0000-0002-4312-966X 0000-0003-1196-369X 0000-0003-0231-8330 0000-0003-0423-9038 |
| OpenAccessLink | http://dx.doi.org/10.3802/jgo.2024.35.e45 |
| PMID | 38216137 |
| PQID | 2929033842 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10410406 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10948989 proquest_miscellaneous_2929033842 pubmed_primary_38216137 crossref_citationtrail_10_3802_jgo_2024_35_e45 crossref_primary_10_3802_jgo_2024_35_e45 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-01 |
| PublicationDateYYYYMMDD | 2024-03-01 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of gynecologic oncology |
| PublicationTitleAlternate | J Gynecol Oncol |
| PublicationYear | 2024 |
| Publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 대한부인종양학회 |
| Publisher_xml | – name: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology – name: 대한부인종양학회 |
| References | Eskander (10.3802/jgo.2024.35.e45_ref15) 2023; 388 Parkin (10.3802/jgo.2024.35.e45_ref1) 1999; 80 Colombo (10.3802/jgo.2024.35.e45_ref19) 2023; 34 Fader (10.3802/jgo.2024.35.e45_ref6) 2020; 26 Matei (10.3802/jgo.2024.35.e45_ref14) 2019; 380 Oaknin (10.3802/jgo.2024.35.e45_ref17) 2022; 10 Buda (10.3802/jgo.2024.35.e45_ref9) 2018; 44 Higgins (10.3802/jgo.2024.35.e45_ref3) 2016; 10 Schlappe (10.3802/jgo.2024.35.e45_ref10) 2018; 151 Lim (10.3802/jgo.2024.35.e45_ref2) 2019; 30 Atkins (10.3802/jgo.2024.35.e45_ref4) 2004; 328 Makker (10.3802/jgo.2024.35.e45_ref5) 2022; 386 Schiavone (10.3802/jgo.2024.35.e45_ref11) 2017; 24 Westin (10.3802/jgo.2024.35.e45_ref18) 2023 Bogani (10.3802/jgo.2024.35.e45_ref13) 2019; 153 ASTEC study group (10.3802/jgo.2024.35.e45_ref8) 2009; 373 Benedetti Panici (10.3802/jgo.2024.35.e45_ref7) 2008; 100 Mirza (10.3802/jgo.2024.35.e45_ref16) 2023; 388 How (10.3802/jgo.2024.35.e45_ref12) 2017; 144 |
| References_xml | – volume: 44 start-page: 1562 year: 2018 ident: 10.3802/jgo.2024.35.e45_ref9 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2018.06.034 – year: 2023 ident: 10.3802/jgo.2024.35.e45_ref18 publication-title: J Clin Oncol – volume: 80 start-page: 827 year: 1999 ident: 10.3802/jgo.2024.35.e45_ref1 publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P – volume: 24 start-page: 1965 year: 2017 ident: 10.3802/jgo.2024.35.e45_ref11 publication-title: Ann Surg Oncol doi: 10.1245/s10434-017-5816-4 – volume: 34 start-page: S1281 year: 2023 ident: 10.3802/jgo.2024.35.e45_ref19 publication-title: Ann Oncol doi: 10.1016/j.annonc.2023.10.034 – volume: 328 start-page: 1490 year: 2004 ident: 10.3802/jgo.2024.35.e45_ref4 publication-title: BMJ doi: 10.1136/bmj.328.7454.1490 – volume: 10 start-page: e003777 year: 2022 ident: 10.3802/jgo.2024.35.e45_ref17 publication-title: J Immunother Cancer doi: 10.1136/jitc-2021-003777 – volume: 388 start-page: 2159 year: 2023 ident: 10.3802/jgo.2024.35.e45_ref15 publication-title: N Engl J Med doi: 10.1056/NEJMoa2302312 – volume: 153 start-page: 676 year: 2019 ident: 10.3802/jgo.2024.35.e45_ref13 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2019.03.254 – volume: 10 start-page: 29 year: 2016 ident: 10.3802/jgo.2024.35.e45_ref3 publication-title: Cochrane Database Syst Rev – volume: 373 start-page: 125 year: 2009 ident: 10.3802/jgo.2024.35.e45_ref8 publication-title: Lancet doi: 10.1016/S0140-6736(08)61766-3 – volume: 144 start-page: 503 year: 2017 ident: 10.3802/jgo.2024.35.e45_ref12 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2017.01.013 – volume: 380 start-page: 2317 year: 2019 ident: 10.3802/jgo.2024.35.e45_ref14 publication-title: N Engl J Med doi: 10.1056/NEJMoa1813181 – volume: 100 start-page: 1707 year: 2008 ident: 10.3802/jgo.2024.35.e45_ref7 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn397 – volume: 26 start-page: 3928 year: 2020 ident: 10.3802/jgo.2024.35.e45_ref6 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-20-0953 – volume: 386 start-page: 437 year: 2022 ident: 10.3802/jgo.2024.35.e45_ref5 publication-title: N Engl J Med doi: 10.1056/NEJMoa2108330 – volume: 151 start-page: 235 year: 2018 ident: 10.3802/jgo.2024.35.e45_ref10 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2018.08.022 – volume: 30 start-page: e38 year: 2019 ident: 10.3802/jgo.2024.35.e45_ref2 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2019.30.e38 – volume: 388 start-page: 2145 year: 2023 ident: 10.3802/jgo.2024.35.e45_ref16 publication-title: N Engl J Med doi: 10.1056/NEJMoa2216334 |
| SSID | ssj0067082 |
| Score | 2.3083024 |
| SecondaryResourceType | review_article |
| Snippet | The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment... The Korean Society of Gynecologic Oncology (KSGO) had been making an effort tostandardize and enhance the quality of domestic uterine corpus cancer treatment... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e45 |
| SubjectTerms | Endometrial Neoplasms - pathology Female Humans Lymph Node Excision Lymph Nodes - pathology Neoplasm Recurrence, Local - pathology Neoplasm Staging Practice Guideline Republic of Korea Sentinel Lymph Node - pathology Sentinel Lymph Node Biopsy Uterine Neoplasms - pathology 산부인과학 |
| Title | Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38216137 https://www.proquest.com/docview/2929033842 https://pubmed.ncbi.nlm.nih.gov/PMC10948989 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003060799 |
| Volume | 35 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Gynecologic Oncology, 2024, 35(2), , pp.1-13 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa6ISFeEPeVm4zgAalKSWMnaXhDsFHG1vHQSuPJih2nLQNn6hqh8Qh_nHNiN2lLkQZSlUauL1G_r_Y59TmfCXmRyDBUia-9PIsjjyc89RLJfC9PM19lPT_PqkTh42E0GPPD0_C01fq1ErVULmRX_diaV_I_qEIZ4IpZsv-AbN0pFMA94AtXQBiuV8L4k0tx6kxKVKvCCPYqbPBbHdOCtiAe2oC2JPiZ5yVqUQPOGITe-ViAxWiznatbU8dwQqv3l0YrOzN2ToyyUk0KY6_NBfRSJSLVUTN_WreTleaFa97s97vUbG9wWZqN0nep9j7rYrP4sDTT7w2Th8W02b9wW1vuv4uAN8FbdoqrdFB9Zo9I6uotZW6OtpImjovByoSrrRjl5kLA-pWw7JcJ5ncGvMvCrqu5Lrk9PBEH46MjMdo_He2Qa0Ec271-9Mvtch7FfnXiWP1YVh8KB3i10f2aabNj5vk2r2Uz-HbFmhndIjcdUPSN5dRt0tLmDrl-7AIt7pKfS2rRhloUqEUbatEip45a1FKLWmrRmaEVn17T1N4Y6oiFbVaIRZfEojWxaE2se2R8sD96O_DccR2eAqNm4QU6liGXmO0cJmkehv0cnIUk45lUMtTaj7XkSuXgUMRJypRkLMujyJdgxUqYFdh9smsKo_cI5UFPKtbLwJ_NuEpzqCLBEk1hcQILNgvapLv8poVyWvZ4pMpXAT4tQiMAGoHQCBYKgKZNXtYNzq2My9-rPgfoxJmaCZRex3eocDYX4GB-gEYcXn7UJs-W0AqYkHGXLTW6KC9EAA6Hz1ifw1M-sFDXQ7J-AB4Wi9ukv0aCugKOuP6JmU0r0feen3A86vXhFQZ-RG40v7bHZHcxL_UTsJ0X8mnF7d9ipstY |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Practice+guidelines+for+management+of+uterine+corpus+cancer+in+Korea%3A+a+Korean+Society+of+Gynecologic+Oncology+consensus+statement&rft.jtitle=Journal+of+gynecologic+oncology&rft.au=Kim%2C+Ju-Hyun&rft.au=Kim%2C+Dae-Yeon&rft.au=Kim%2C+Junhwan&rft.au=Noh%2C+Joseph+J&rft.date=2024-03-01&rft.issn=2005-0399&rft.eissn=2005-0399&rft.volume=35&rft.issue=2&rft.spage=e45&rft_id=info:doi/10.3802%2Fjgo.2024.35.e45&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-0380&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-0380&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-0380&client=summon |